Prognostic value of PD-L1 expression and association with HRD in high-grade serous ovarian cancer: an ancillary analysis of the PAOLA-1/ENGOT-ov25 trial (GINECO).
Specific immune profiles in ovarian cancer predict better survival chances, helping oncologists tailor treatment to each patient's biology.
This biomarker ancillary analysis of a phase 3 randomized trial evaluated Prognostic value of PD-L1 expression and association with HRD in high-grade serous ovarian cancer: an ancillary analysis of the PAOLA-1/ENGOT-ov25 trial (GINECO). The PubMed abstract reports that in advanced HGSOC, standardized whole-slide PD-L1 assessment identifies an HRD-associated PD-L1-positive immune context independently associated with improved overall survival.
What the study was
- Study design
- Biomarker ancillary analysis of a phase 3 randomized trial
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- ESMO open
Why it surfaced
Biomarker ancillary analysis of a phase 3 randomized trial with abstract-backed evidence relevant to Precision oncology and genomic medicine; the score reflects study maturity, clinical relevance, and population or unmet-need considerations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.